Sunshine Biopharma (SBFM) Projected to Release Earnings on Tuesday

Sunshine Biopharma (NASDAQ:SBFM) will likely be issuing its results before the market opens on Tuesday, August 11th. Analysts expect Sunshine Biopharma to announce earnings of ($1.20) per share and revenue of $8.70 million for the quarter.

Sunshine Biopharma (NASDAQ:SBFM) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.60) by $1.35. The company had revenue of $8.09 million for the quarter, compared to the consensus estimate of $9.20 million. Sunshine Biopharma had a negative net margin of 18.45% and a negative return on equity of 27.75%.

Sunshine Biopharma Stock Up 15.8%

SBFM stock traded up $0.18 during mid-day trading on Tuesday, hitting $1.35. The company had a trading volume of 1,580,052 shares, compared to its average volume of 709,763. The company has a market capitalization of $677,500.00, a price-to-earnings ratio of -0.11 and a beta of 1.17. Sunshine Biopharma has a 12-month low of $1.10 and a 12-month high of $24.30. The company has a 50-day moving average price of $2.13 and a 200 day moving average price of $7.56.

Institutional Trading of Sunshine Biopharma

A number of large investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of Sunshine Biopharma during the 4th quarter valued at about $29,000. Two Sigma Investments LP purchased a new position in Sunshine Biopharma in the third quarter worth about $32,000. Finally, Citadel Advisors LLC grew its position in Sunshine Biopharma by 23.1% in the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after acquiring an additional 14,656 shares in the last quarter. 41.98% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sunshine Biopharma in a report on Friday, July 17th. Zacks Research upgraded Sunshine Biopharma to a “hold” rating in a report on Wednesday, May 27th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $70.00.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.